# Retatrutide's Phase 3, and the Gray Market

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/retatrutide-phase-3-and-the-gray-market

> A triple-receptor agonist cut HbA1c 1.94 points and weight 15.3% in a phase 3 trial. It is approved nowhere, and eight sellers in our register are already shipping something by that name.

## Key points

- HbA1c −1.94 and weight −15.3% on 12 mg at 40 weeks vs −0.81 / −2.6% on placebo.
- Approved in zero countries. No label, no manufacturer of record, no compounding pathway.
- Everyone enrolled was drug-naive, mean 2.5 years since diagnosis, the population where every agent looks best.
- 40 weeks, and weight was the SECONDARY endpoint. Not comparable to a 72-week obesity trial.
- Eight sellers in our register offer it. None of them are selling what was tested.

A phase 3 trial of retatrutide, a single molecule that hits three receptors instead of one or two, reported HbA1c down 1.94 points and weight down 15.3% at 40 weeks on its top dose.[1] It is a real result from a real trial. It is also a result for a drug you cannot legally be prescribed, and the eleven sellers our register had counted offering something called retatrutide by August 2026 are not selling what was studied.

## What was tested

TRANSCEND-T2D-1 enrolled 537 adults across 48 sites in the United States, Mexico and India, all of whom had type 2 diabetes that diet and exercise alone were not controlling, an HbA1c between 7.0% and 9.5%, and a BMI of at least 23. They were assigned in equal quarters to weekly injections of retatrutide at 4, 9 or 12 mg, or to placebo, for 40 weeks. The question was HbA1c; weight was a secondary endpoint.

*TRANSCEND-T2D-1 at 40 weeks, treatment-regimen estimand. Baseline HbA1c 7.9%, BMI 35.8.[1]*

| Arm | HbA1c change | vs placebo | Weight change |
| --- | --- | --- | --- |
| Retatrutide 4 mg | −1.69% | −0.88 (−1.18 to −0.59) | −11.5% |
| Retatrutide 9 mg | −1.86% | −1.04 (−1.32 to −0.76) | −13.9% |
| Retatrutide 12 mg | −1.94% | −1.12 (−1.39 to −0.85) | −15.3% |
| Placebo | −0.81% | — | −2.6% |

Every dose beat placebo at p<0.0001, and no severe hypoglycemia occurred. Tolerability was unremarkable for the class, with gut effects that faded and discontinuations of 2% to 5% against 0% on placebo. Two deaths were recorded, both in the 4 mg arm, both judged unrelated.

## Read the population before reading the numbers

> **These participants had never been treated with a diabetes drug.** Enrollment required diabetes inadequately controlled by *diet and exercise alone*, average duration was 2.5 years, and average age was 48.8. Early, untreated, comparatively young diabetes is the setting where every agent in this field posts its best figures. This is monotherapy in the most responsive population available, not add-on therapy in a difficult one.

That is not a criticism of the trial. Monotherapy in drug-naive patients is a legitimate and necessary question, and it is what the trial says it studied. The caution is against reading these numbers as what retatrutide would do for someone ten years into diabetes on three medications.

Resist one other comparison. Forty weeks is shorter than the 68- and 72-week obesity trials most readers have in their heads, and weight here was secondary to blood sugar. A 15.3% figure at 40 weeks in a diabetes trial is not the same object as a percentage from a dedicated obesity trial run half again as long, and we are not going to set them side by side.

## The part that concerns this register

Retatrutide is not approved for any use, in any country. It has no FDA label, no prescribing information, no approved manufacturer, and no legal pathway to a pharmacy. A good phase 3 result does not change any of that, and it does something worse in the short term: **it raises demand for a drug the legitimate supply chain cannot fill.**

> The trial and the vial are different objects. A published result tells you nothing about what is in an unlabeled bottle.

In the trial, participants received material manufactured to clinical-trial standard, at a verified concentration, with a known impurity profile, injected on a schedule supervised by a study team. None of those properties transfer to a vial bought online, and every one of them is load-bearing for the result above. A powder sold as retatrutide has no independent verification of identity, purity, concentration, sterility or stability, because there is no approved product to verify it against.

> **Retatrutide also cannot lawfully be compounded.** The FDA says federal law bars it from compounding, and it is not a component of any approved drug, so it has no legitimate compounding route.[3] Anything offered as compounded retatrutide is outside that framework entirely (the mechanics are in [what cannot legally be compounded](https://glpwatchdog.org/research/what-cannot-legally-be-compounded)).

We track sellers offering it because a reader deserves to know before they order, not after. The register’s standing coverage is in [retatrutide: what the evidence shows](https://glpwatchdog.org/research/retatrutide-what-the-evidence-shows), and the pattern of research-chemical marketing generally is in [research chemical listings](https://glpwatchdog.org/research/buy-tirzepatide-research-chemical), and what FDA has written to those sellers is in [FDA warning letters to peptide sellers](https://glpwatchdog.org/research/fda-warning-letters-to-peptide-sellers).

## What would change this

- **An FDA approval**, which brings a label, a manufacturer of record, and a defined dose and schedule in place of [the trial dosing protocols](https://glpwatchdog.org/research/retatrutide-dosing-in-the-trials). Lilly’s target for filing is Q1 2027, and nothing has been filed yet.[2]
- **Cardiovascular and kidney outcome data.** Blood sugar and weight are intermediate endpoints. Glucagon receptor agonism is a new element in this class, and what it does to hard outcomes over years is unestablished.
- **Longer trials.** Forty weeks is a snapshot for a drug intended to be taken indefinitely.
- **Data in harder populations**, with longer diabetes duration, existing therapy and older patients.

Until then, the summary is short. The science is promising, the drug is unapproved, and what is for sale is not the drug in the trial. The same holds for [tesofensine](https://glpwatchdog.org/research/tesofensine-what-the-evidence-shows), an older pill still waiting on approval in Mexico, and for [VK2735](https://glpwatchdog.org/research/another-molecule-you-cannot-buy), a newer dual agonist whose headline number comes from a thirteen-week trial.

## Frequently asked questions

### Is retatrutide approved?

No. It has no approval in any country, no FDA label, and no legal route to a pharmacy. Lilly's target for an FDA filing is Q1 2027.

### How well did it work in the trial?

In TRANSCEND-T2D-1, the 12 mg dose lowered HbA1c by 1.94 points against 0.81 on placebo and reduced weight by 15.3% against 2.6%, over 40 weeks, in adults whose type 2 diabetes had not previously been treated with medication.

### Does a good trial result mean it is safe to buy online?

No, and the two are unrelated. Trial participants received material made to clinical-trial standard at a verified concentration with a known impurity profile. A vial bought online has no verification of identity, purity, concentration or sterility, because there is no approved product to check it against.

### Can a compounding pharmacy make it?

Not lawfully. The FDA says retatrutide cannot be used in compounding under federal law, and it is not an ingredient of any approved drug, so there is no legitimate compounding pathway for it.

### Why were the weight numbers so high in a diabetes trial?

Partly the drug and partly the population. Everyone enrolled was managing diabetes with diet and exercise alone, averaging 2.5 years since diagnosis. Early, untreated diabetes is where every drug in this class produces its strongest results.

## References

1. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026. PMID: 42250575. https://pubmed.ncbi.nlm.nih.gov/42250575/
2. Eli Lilly and Company Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. PR Newswire — company press release. 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-substantial-weight-loss-and-a1c-reduction-underscoring-its-potential-promise-for-people-with-obesity-and-type-2-diabetes-302891798.html
3. U.S. Food and Drug Administration FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — drug alert, content current as of October 1, 2026. FDA. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

---

Cite as: GLP Watchdog, Nora Bissett, "Retatrutide's Phase 3, and the Gray Market", published 2026-08-20, updated 2026-11-02. https://glpwatchdog.org/research/retatrutide-phase-3-and-the-gray-market

Canonical HTML page: https://glpwatchdog.org/research/retatrutide-phase-3-and-the-gray-market

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
